Source-grounded facts extracted from Rallybio Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Rallybio Corp entered into Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc. (effective 2026-05-31).
“On May 31, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Avenzo Therapeutics, Inc., a Delaware corporation (“ Avenzo ”)”
Rallybio Corp terminated Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. valued at $50,000,000 Parent Termination Fee (effective 2026-05-03).
“On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permitted Alternative Agreement (as defined in the Merger Agreement) with UCB S.A. (“ UCB ”).”
Rallybio Corp entered into Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. (effective 2026-03-01).
“On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”)”
Rallybio Corp: Effected a 1-for-8 reverse stock split of common stock via Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2026-02-06).
“On January 26, 2026, Rallybio Corporation (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 (the “Common Stock”) at a ratio of 1-for-8 (the “Reverse Stock Split”). Pursuant to the Certificate of Amendment, the Reverse Stock Split will be effective at 12:01 a.m., Eastern Time, on February 6, 2026.”
Rallybio Corp received a nasdaq noncompliance notice notice regarding minimum bid price.
“February 24, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the prior 30 consecutive business days (the “Notice”), as required for continued listing on the Nasdaq. Pursuant to Nasdaq’s Listing Rules, the Company had until August 25, 2025 (the “Initial Compliance Date”) to regain compliance with the minimum closing bid price requirement. As of the Initial Complian”
Rallybio Corp completed a disposition involving Recursion Pharmaceuticals, Inc. (closed 2025-07-08).
“On July 8, 2025, Rallybio Corporation (“Rallybio”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Recursion Pharmaceuticals, Inc., (“Recursion”), Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion (“Buyer”) and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio (“Seller”), pursuant to which Buyer purchased 50% of the issued and outstanding membership interests (the “Membership Interests”) of RE Ventures I, LLC (the “ENPP1 JV”) from Seller in exchange for cash and the issuance of shares (“Shares”) of Class A Common Stock of Recursion (the “Sale”).”
Rallybio Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“February 24, 2025, Rallybio Corporation (the “Company” or “Rallybio”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive business days (the “Notice”), as required for continued listing on the Nasdaq under Rule 5450(a)(1) of the Nasdaq’s Listing Rules (the “Rules”). The Notice has no immediate impact on the listing of the Company’s common stock, wh”
Kush Parmar resigned as Member of the Board and Chair of the Nominating and Corporate Governance Committee at Rallybio Corp.
“On September 16, 2024, Dr. Kush Parmar informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he intends to resign as a member of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board effective October 31, 2024.”
Martin Mackay resigned as Executive Chairman at Rallybio Corp.
“On July 23, 2024, Martin Mackay, Ph.D., informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he will resign his Executive Chairman role and his employment with Rallybio, effective December 31, 2024.”
Rallybio Corp reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Rallybio Corp entered into Securities Purchase Agreement with Johnson & Johnson Innovation – JJDC, Inc. valued at approximately $6.6 million (effective 2024-04-10).
“On April 10, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Johnson & Johnson Innovation – JJDC, Inc., a Delaware corporation (the “Purchaser”), pursuant to which the Company sold to the Purchaser, in an unregistered offering (the “Offering”), shares of common stock”
Rallybio Corp entered into Collaboration Agreement with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. valued at $0.5 million (effective 2024-04-09).
“On April 9, 2024, Rallybio Corporation (the “Company”), through its subsidiary Rallybio IPA, LLC, entered into a collaboration agreement (the “Collaboration Agreement”) with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (“J&J”),”
Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2023.
“On March 12, 2024, Rallybio Corporation issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.”
Rallybio Corp announced a restructuring with charges of approximately $3.3 million affecting Rallybio (approximately 45% of its current positions).
“On February 6, 2024, Rallybio announced the prioritization of its portfolio and a workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116. As part of this effort, Rallybio will eliminate approximately 45% of its current positions. As a result of these actions, Rallybio expects to incur charges of approximately $3.3 million, excluding share-based compensation expense.”
Rallybio Corp reported the third quarter ended September 30, 2023 results: net income Net loss was $18.4 million for the third quarter of 2023, or net loss per common share of $0.45, EPS net loss per common share of $0.45.
“Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023”
Rallybio Corp reported the second quarter ended June 30, 2023 results: net income Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46, EPS $0.46.
“On August 8, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter ended June 30, 2023.”
Martin Mackay was appointed as Executive Chairman at Rallybio Corp.
“Dr. Mackay, who has served as Chief Executive Officer and Chairman of the Board since 2018, has been appointed to Executive Chairman, effective August 1, 2023.”
Stephen Uden was appointed as Chief Executive Officer at Rallybio Corp.
“On June 28, 2023, the Board of Directors (the Board) of Rallybio Corporation (Rallybio) appointed Stephen Uden, M.D., Rallybio’s President, Chief Operating Officer and Co-Founder since January 2018, to Chief Executive Officer, effective August 1, 2023.”
Rallybio Corp shareholders approved Ratification of appointment of Deloitte and Touche LLP as independent auditor at the 2023-05-17 meeting.
“The shareholders ratified the appointment of Deloitte and Touche LLP as the independent registered public accounting firm for Rallybio for the fiscal year ending December 31, 2023. For Against Abstain 27,911,030 4,866 230”
Rallybio Corp shareholders approved Election of Class II directors at the 2023-05-17 meeting.
“The following nominees were elected to the Board of Directors as Class II directors for terms expiring at the 2025 annual meeting of shareholders. For Against Abstentions/Broker Non-Votes Helen Boudreau 18,762,070 6,047,659 3,106,397 Lucian Iancovici 18,875,144 5,934,499 3,106,483 Christine Nash 18,763,528 6,046,201 3,106,397”
Rallybio Corp reported first quarter ended March 31, 2023 results: net income $17.3 million, EPS $0.43.
“Net loss was $17.3 million for the first quarter of 2023, or net loss per common share of $0.43 compared to a net loss of $14.5 million, or net loss per common share of $0.48 for the first quarter of 2022.”
Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2022.
“On March 6, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
Jonathan I. Lieber was appointed as Chief Financial Officer and Treasurer at Rallybio Corp.
“On January 31, 2023, the Board of Directors (the Board) of Rallybio Corporation (Rallybio) appointed Jonathan I. Lieber as Chief Financial Officer and Treasurer, effective February 1, 2023.”
Rallybio Corp entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. (effective 2022-11-10).
“On November 10, 2022, Rallybio Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), relating to the underwritten offering of 5,000,001 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $6.00 per Share, less the underwriting discounts and commissions, and, to certain investors in lieu of Common Stock, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of Common Stock at a price of $5.9999 (the “Pre-Funded Warrants”), which represents the per share public offering price for the Shares less the $0.0001 per share exercise price for each Pre-Funded Warrant (the “Offering”).”
Rallybio Corp reported financial results for the quarter ended September 30, 2022.
“On November 7, 2022, Rallybio Corporation issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Wendy K. Chung, M.D., Ph.D. was appointed as director at Rallybio Corp.
“the Board increased its size from nine directors to ten directors and appointed Wendy K. Chung, M.D., Ph.D. to serve as a director to fill the newly created vacancy, effective August 1, 2022.”
Jeffrey M. Fryer departed as Chief Financial Officer at Rallybio Corp.
“On June 2, 2022, Rallybio Corporation (Rallybio) announced that Jeffrey M. Fryer will retire as Rallybio’s Chief Financial Officer (CFO).”
Timothy Shannon resigned as Director at Rallybio Corp.
“Timothy Shannon notified Rallybio that he would resign from the Board, effective at Rallybio’s 2022 annual meeting of shareholders.”
Hui Liu was appointed as Director at Rallybio Corp.
“appointed Christine A. Nash and Hui Liu, Ph.D., each to serve as a director to fill the newly created vacancies, effective April 4, 2022.”
Christine A. Nash was appointed as Director at Rallybio Corp.
“appointed Christine A. Nash and Hui Liu, Ph.D., each to serve as a director to fill the newly created vacancies, effective April 4, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.